**Semaglutide** investigated for metabolic state deterioration prevention in antipsychotic-treated schizophrenia patients.
Response to Comment on Ganeshalingam et al. Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly.
Abstract
The HISTORI trial examines if semaglutide 1.0 mg weekly improves insulin sensitivity and β-cell function in schizophrenia patients on antipsychotics.
TitrateLab articles covering Semaglutide
Written by TitrateLab, separately from the study summarized above.
